ZIOP - ZIOPHARM Oncology, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.17
-0.05 (-2.25%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.22
Open2.22
Bid2.14 x 2900
Ask2.26 x 1000
Day's Range2.14 - 2.27
52 Week Range2.14 - 5.25
Volume1,533,810
Avg. Volume1,279,907
Market Cap306.363M
Beta (3Y Monthly)1.51
PE Ratio (TTM)N/A
EPS (TTM)-0.53
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.25
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Ziopharm Oncology Announces Changes to Board of Directors and Management Team

    BOSTON, Oct. 16, 2018 (GLOBE NEWSWIRE) --  Ziopharm Oncology, Inc. (ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced changes to its Board of Directors and management team. Ziopharm’s Chief Executive Officer Laurence Cooper, M.D., Ph.D, is appointed to the Board of Directors effective immediately, and Francois Lebel, M.D., is stepping down from his position as Chief Medical Officer (CMO) and Executive Vice President of Research & Development, effective Oct. 26.

  • GlobeNewswire14 days ago

    Ziopharm and Precigen Redefine Relationships, Announce New License Agreement

    Ziopharm to Host Conference Call at 8 a.m. Through the new agreement, Ziopharm will primarily focus its resources on developing its Controlled IL-12 and Sleeping Beauty (SB) T-cell receptor (TCR) platform technologies which have the capability to treat solid tumors, while Intrexon further establishes Precigen as a therapeutics company concentrating on immuno-oncology, autoimmune and infectious disease therapies. With this exclusive license, Ziopharm now has full developmental control and exclusivity utilizing SB for TCRs targeted towards neoantigens and public antigens.

  • GlobeNewswire28 days ago

    Ziopharm Oncology to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

    Ziopharm Oncology, Inc. (ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference in New York on Tuesday, Oct. 2, at 2:15 p.m. ET. Ziopharm Oncology is a Boston-based biotechnology company focused on the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer. In partnership with Precigen Inc., a wholly-owned subsidiary of Intrexon Corporation (XON), Ziopharm is focused on the development of two platform technologies designed to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of multiple cancer types: Controlled IL-12 and Sleeping Beauty for genetically modifying T cells.

  • Should You Have ZIOPHARM Oncology Inc’s (NASDAQ:ZIOP) In Your Portfolio?
    Simply Wall St.last month

    Should You Have ZIOPHARM Oncology Inc’s (NASDAQ:ZIOP) In Your Portfolio?

    If you own shares in ZIOPHARM Oncology Inc (NASDAQ:ZIOP) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...

  • Is the Options Market Predicting a Spike in ZIOPHARM Oncology (ZIOP) Stock?
    Zackslast month

    Is the Options Market Predicting a Spike in ZIOPHARM Oncology (ZIOP) Stock?

    Investors need to pay close attention to ZIOPHARM Oncology (ZIOP) stock based on the movements in the options market lately.

  • GlobeNewswire2 months ago

    CORRECTING and REPLACING -- Ziopharm Oncology Announces Scott Braunstein, M.D., Operating Partner at Aisling Capital, Nominated to Board of Directors

    In a release issued earlier today by Ziopharm Oncology, Inc. (ZIOP), please note the Company's upcoming annual meeting of stockholders is being held Sept. 18 rather than Sept. 8 as originally issued. Ziopharm Oncology, Inc. (ZIOP) today announced that its Board of Directors has nominated Scott Braunstein, M.D., an Operating Partner at Aisling Capital, a leading healthcare investment firm, for election to the Board of Directors at the Company’s annual meeting of stockholders on Sept. 18. In addition to Aisling Capital, Dr. Braunstein has held leadership positions including serving as the Chief Operating Officer at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company.

  • GlobeNewswire2 months ago

    Ziopharm Oncology Announces Scott Braunstein, M.D., Operating Partner at Aisling Capital, Nominated to Board of Directors

    Ziopharm Oncology, Inc. (ZIOP) today announced that its Board of Directors has nominated Scott Braunstein, M.D., an Operating Partner at Aisling Capital, a leading healthcare investment firm, for election to the Board of Directors at the Company’s annual meeting of stockholders on Sept. 8. In addition to Aisling Capital, Dr. Braunstein has held leadership positions including serving as the Chief Operating Officer at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ZIOP earnings conference call or presentation 8-Aug-18 8:30pm GMT

    Q2 2018 ZIOPHARM Oncology Inc Earnings Call

  • PR Newswire2 months ago

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Ziopharm Oncology, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , Aug. 14, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool2 months ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these fast-rising biotech stocks keep the momentum going?

  • Why Ziopharm Oncology Is Soaring 14% Today
    Motley Fool2 months ago

    Why Ziopharm Oncology Is Soaring 14% Today

    The company's second-quarter update is fueling optimism.

  • Ziopharm Oncology (ZIOP) Reports Q2 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Ziopharm Oncology (ZIOP) Reports Q2 Loss, Lags Revenue Estimates

    Ziopharm (ZIOP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Ziopharm: 2Q Earnings Snapshot

    The Boston-based company said it had a loss of 12 cents per share. The results met Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was also for a loss ...

  • GlobeNewswire2 months ago

    Ziopharm Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    Ziopharm Oncology, Inc. (ZIOP), today announced financial results for the second quarter ended June 30, 2018, and provided an update on the Company’s recent activities. “Our Controlled IL-12 and Sleeping Beauty platforms address the major problems in immuno-oncology which are targeting solid tumors and reducing the costs and complexities of T-cell therapies,” said Laurence Cooper, M.D., Ph.D., CEO of Ziopharm. “Our team is focused on addressing the FDA’s request for more information to lift the clinical hold on the third-generation Phase 1 trial to evaluate CD19-specific T cells produced in under two days using the Sleeping Beauty system.

  • ACCESSWIRE2 months ago

    ZIOPHARM Oncology, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 PM Eastern ...

  • Why Ziopharm Oncology Stock Zoomed 16.8% Higher Today
    Motley Fool3 months ago

    Why Ziopharm Oncology Stock Zoomed 16.8% Higher Today

    A game of musical chairs on its board of directors causes investors to sing a new tune about this beaten-down biotech.

  • GlobeNewswire3 months ago

    Ziopharm Oncology Announces Changes to its Board of Directors

    Scott Tarriff, a member of the Board since 2015, has been elected to serve as Lead Director, succeeding Sir Murray Brennan, M.D. Both Sir Dr. Brennan and former U.S. Sen. William Wyche Fowler will step down when their terms expire on September 18, 2018, the date of the annual meeting of shareholders. Doug Pagán and Elan Ezickson have been nominated for election to the Board at the Company’s annual meeting of stockholders.

  • GlobeNewswire3 months ago

    Ziopharm Oncology to Announce Second Quarter 2018 Financial Results, Host Conference Call Aug. 8

    The webcast will be recorded and available for replay on the Company's website for two weeks. Ziopharm Oncology is a Boston-based biotechnology company focused on the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer. In partnership with Precigen Inc., a wholly-owned subsidiary of Intrexon Corporation (XON), Ziopharm is focused on the development of two platform technologies designed to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of multiple cancer types: Controlled IL-12 and Sleeping Beauty for genetically modifying T cells.

  • ACCESSWIRE3 months ago

    Breakfast Technical Briefing on ZIOPHARM Oncology and Three Other Additional Biotech Stocks

    For today, WallStEquities.com assesses vTv Therapeutics Inc. (NASDAQ: VTVT), Voyager Therapeutics Inc. (NASDAQ: VYGR), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Zosano Pharma Corp. (NASDAQ: ZSAN). High Point, North Carolina headquartered vTv Therapeutics Inc.'s stock saw a decline of 3.70%, finishing last Friday's trading session at $1.30. The Company's shares are trading below their 50-day moving average by 19.58%.

  • GlobeNewswire3 months ago

    Ziopharm Oncology Board Responds to Recent Stock Price Decline

    Ziopharm Oncology, Inc. (ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today responded to the recent stock price decline and announced it expects to add new members to the Company’s Board of Directors and expand its management team. “Over the past year, our Controlled IL-12 and Sleeping Beauty cell therapy platform technologies have progressed, providing a strong scientific foundation for the Company.

  • Why Ziopharm Oncology Stock Fell by 27% Halfway Through 2018
    Motley Fool3 months ago

    Why Ziopharm Oncology Stock Fell by 27% Halfway Through 2018

    Ziopharm has been stung by a series of clinical setbacks this year, and the company is now facing a serious cash crunch to boot.

  • ACCESSWIRE4 months ago

    Initiating Free Research Reports on ZIOPHARM Oncology and Three Other Biotech Equities

    Stock Research Monitor: VYGR, VTVT, and ZSAN LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want a free Stock Review on ZIOP sign up now at www.wallstequities.com/registration . WallStEquities.com recalls ...

  • Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics
    Motley Fool4 months ago

    Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics

    Which beaten-down biotech stock wins in a head-to-head match-up?